Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.48 |
| ▸ | CA1 | P00915 | 11/20 | 0.48 |
| ▸ | CA12 | O43570 | 8/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA5A | P35218 | 3/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26028733 | 0.81 | MAOB (0.47) | SMN1; SMN2 | |
| SCHEMBL8000283 | 0.79 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19507322 | 0.79 | CA2 (0.36) | CA2CA1CA12CA4CA9 | |
| SCHEMBL12567063 | 0.75 | CYP3A4 (0.41) | — | |
| SCHEMBL8260632 | 0.74 | CA2 (0.63) | CA2CA1CA12CA4CA9 | |
| SCHEMBL16130747 | 0.74 | NPC1 (0.33) | — | |
| SCHEMBL19507070 | 0.74 | LOXL2 (0.34) | CA2CA1CA12CA4CA9 | |
| SCHEMBL16091697 | 0.73 | MAOB (0.50) | SMN1; SMN2 | |
| SCHEMBL10249975 | 0.73 | CYP4F2 (0.52) | — | |
| SCHEMBL13355355 | 0.72 | LTB4R (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610247-B1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LTD (BS) | 2016-05-25 | — | — | EP | disclosed |
| EP-2265589-B1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LTD (BS) | 2016-01-27 | — | — | EP | disclosed |
| US-9126942-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2015-09-08 | — | — | US | disclosed |
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LIMITED (BS) | 2015-02-19 | — | — | US | disclosed |
| US-8901108-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-01-09 | — | — | US | disclosed |
| US-8563723-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2610247-A1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | Abbott Healthcare Products B.V. (NL) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HOSPITALS LIMITED (BS) | 2011-02-24 | — | — | US | disclosed |
| WO-2009115515-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | CA2 4148/4885CA1 3815/4885CA12 4321/4885 |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | CA2 4148/4885CA1 3815/4885CA12 4321/4885 |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | CA2 4148/4885CA1 3815/4885CA12 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.